Spero Therapeutics, Inc. (SPRO)
NasdaqGS · USD · Healthcare · Biotechnology
$1.06 (-1.40%) as of
Key statistics
- Market cap
- 61.44M
- P/E (TTM)
- 7.54
- Forward P/E
- -0.95
- EPS (TTM)
- 0.1400
- Dividend yield
- 0.00%
- 52-week range
- 1.0500 – 3.0800
- Beta
- 1.50
- Revenue (TTM)
- 47M
- Profit margin
- 15.71%
- Analyst target
- $5.00
- Volume
- 59.82k
About Spero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Cambridge, MA, United States
- Employees
- 25
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.